SEC Form 4 · accession 0001209191-16-155448
EAGLE PHARMACEUTICALS, INC. · EGRX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Steven L. Krill
Officer — EVP & Chief Scientific Officer
Period of report
Dec 13, 2016
Accepted (ET)
Dec 15, 2016 · 4:57 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000827871
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Dec 13, 2016 | M | 10,000 | $4.42 | A | 10,000 | D | |
| Common Stock | Dec 13, 2016 | S | 10,000 | $73.6163 | D | 0 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $4.42 | Dec 13, 2016 | M | 10,000 | D | — | Apr 18, 2023 | Common Stock | 10,000 | 9,210 | D |
Explanation of responses
- F125% of the shares subject to the option vested on April 19, 2014 and the remainder shall vest in equal monthly installments over a period of three years.